EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Recommendation Paper on Advancing the Use of Decentralised Elements in Clinical Trials

Alison Bond, Tracey Robertson, Christine Fletcher, Elizabeth Theogaraj, Greg Jordinson, Scott Askin

Therapeutic Innovation & Regulatory Science · 2025-11 · 59 (6) · 1211-1218

DOI: 10.1007/s43441-025-00796-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 27.05.2025. Verfasst von Alison Bond und 5 weiteren Autor:innen. Beteiligte Einrichtung: Director, Global Regulatory Policy and Intelligence, Amgen Ltd, 4 Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, United Kingdom. abond01@…. Hauptthemen laut MEDLINE: Clinical Trials as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The expansion of the use of decentralised elements in clinical trials in the European Union is driven by the opportunities they offer, including their potential to enhance trial access and improve research outcomes. Despite these potential benefits, several regulatory, operational, and technological challenges impede their widespread adoption. This paper, developed by members of the European Federation of Pharmaceutical Industries and Associations, proposes strategies and policy recommendations to overcome these barriers. Through harmonised regulatory frameworks, improved data validation methods, and increased stakeholder collaboration, the use of decentralised elements could become a standard practice in clinical research as part of the clinical trial toolbox to be deployed as appropriate, thereby enabling innovation and allowing for equitable access to clinical trials for diverse populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicHumansEuropean UnionDrug IndustryResearch Design

Stichwörter der Autor:innen

AccessClinical trialsDecentralised clinical trialsInnovationRare diseases

Autor:innen und Institutionen

  • Director, Global Regulatory Policy and Intelligence, Amgen Ltd, 4 Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, United Kingdom. abond01@amgen.com.
  • Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
  • GSK, Stevenage, United Kingdom.
  • Roche, Basel, Switzerland.
  • Johnson & Johnson, High Wycombe, United Kingdom.
  • Novartis, Basel, Switzerland.

Zitieren

APA

Bond, A., Robertson, T., Fletcher, C., Theogaraj, E., Jordinson, G., & Askin, S. (2025). Recommendation Paper on Advancing the Use of Decentralised Elements in Clinical Trials. Therapeutic Innovation & Regulatory Science, 59(6), 1211-1218. https://doi.org/10.1007/s43441-025-00796-w

Vancouver

Bond A, Robertson T, Fletcher C, Theogaraj E, Jordinson G, Askin S. Recommendation Paper on Advancing the Use of Decentralised Elements in Clinical Trials. Therapeutic Innovation & Regulatory Science. 2025;59(6):1211-1218. doi:10.1007/s43441-025-00796-w

BibTeX
@article{Bond2025,
  author = {Bond, Alison and Robertson, Tracey and Fletcher, Christine and Theogaraj, Elizabeth and Jordinson, Greg and Askin, Scott},
  title = {Recommendation Paper on Advancing the Use of Decentralised Elements in Clinical Trials},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2025},
  volume = {59},
  number = {6},
  pages = {1211--1218},
  doi = {10.1007/s43441-025-00796-w}
}
Kostenlos starten →